MYGN moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 24 of 33 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 73%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on MYGN as a result. In 63 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for MYGN just turned positive on October 20, 2026. Looking at past instances where MYGN's MACD turned positive, the stock continued to rise in 27 of 38 cases over the following month. The odds of a continued upward trend are 71%.
The 10-day moving average for MYGN crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where MYGN advanced for three days, in 199 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
The Aroon Indicator entered an Uptrend today. In 111 of 160 cases where MYGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
MYGN broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. MYGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.832) is normal, around the industry mean (66.137). P/E Ratio (-4.932) is within average values for comparable stocks, (2.464). Projected Growth (PEG Ratio) (1.236) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.448) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
NEO's Aroon Indicator triggered a bullish signal on September 30, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 189 similar instances where the Aroon Indicator showed a similar pattern. In 153 of the 189 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 81%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 59 cases where NEO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on NEO as a result. In 62 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
Following a +3.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where NEO advanced for three days, in 215 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
NEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day RSI Indicator for NEO moved out of overbought territory on September 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 28 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NEO turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 39 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
NEO moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NEO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.713) is normal, around the industry mean (66.137). P/E Ratio (-42.538) is within average values for comparable stocks, (2.464). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. NEO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
MYGN | NEO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 47 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 61 Fair valued | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 92 | |
PRICE GROWTH RATING 1..100 | 38 | 37 | |
P/E GROWTH RATING 1..100 | 38 | 63 | |
SEASONALITY SCORE 1..100 | 90 | 43 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NEO's Valuation (27) in the Medical Or Nursing Services industry is somewhat better than the same rating for MYGN (61) in the Biotechnology industry. This means that NEO’s stock grew somewhat faster than MYGN’s over the last 12 months.
NEO's Profit vs Risk Rating (100) in the Medical Or Nursing Services industry is in the same range as MYGN (100) in the Biotechnology industry. This means that NEO’s stock grew similarly to MYGN’s over the last 12 months.
NEO's SMR Rating (92) in the Medical Or Nursing Services industry is in the same range as MYGN (97) in the Biotechnology industry. This means that NEO’s stock grew similarly to MYGN’s over the last 12 months.
NEO's Price Growth Rating (37) in the Medical Or Nursing Services industry is in the same range as MYGN (38) in the Biotechnology industry. This means that NEO’s stock grew similarly to MYGN’s over the last 12 months.
MYGN's P/E Growth Rating (38) in the Biotechnology industry is in the same range as NEO (63) in the Medical Or Nursing Services industry. This means that MYGN’s stock grew similarly to NEO’s over the last 12 months.
| MYGN | NEO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 4 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 72% | 2 days ago 72% |
| MACD ODDS (%) | 2 days ago 71% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 70% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 84% |
| Advances ODDS (%) | 2 days ago 71% | 4 days ago 77% |
| Declines ODDS (%) | 12 days ago 85% | 6 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 78% | 2 days ago 67% |
| Aroon ODDS (%) | 2 days ago 69% | 2 days ago 81% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MYGN’s FA Score shows that 0 FA rating(s) are green while NEO’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MYGN’s TA Score shows that 6 TA indicator(s) are bullish while NEO’s TA Score has 5 bullish TA indicator(s).
MYGN (@Medical Specialties) experienced а +46.23% price change this week, while NEO (@Medical Specialties) price change was -0.36% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.55%. For the same industry, the average monthly price growth was -5.91%, and the average quarterly price growth was +42.02%.
MYGN is expected to report earnings on Nov 04, 2026.
NEO is expected to report earnings on Oct 28, 2026.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IFLN | 17.29 | 0.02 | +0.12% |
| Invesco Bloomberg Enhanced Fallen Angels ETF (IFLN) | |||
| TYYY | 36.33 | N/A | N/A |
| XETFs Tsla Daily Income ETF | |||
| AQWA | 18.74 | -0.05 | -0.24% |
| Global X Clean Water ETF (AQWA) | |||
| SPYC | 44.75 | -0.27 | -0.60% |
| Simplify US Equity PLUS Convexity ETF (SPYC) | |||
| ETW | 9.32 | -0.09 | -0.96% |
| Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund | |||
A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To MYGN | 1D Price Change % | ||
|---|---|---|---|---|
| MYGN | 100% | +1.04% | ||
| VCYT - MYGN | 46% Loosely correlated | +4.11% | ||
| FLGT - MYGN | 41% Loosely correlated | +0.55% | ||
| ADPT - MYGN | 37% Loosely correlated | +4.51% | ||
| NEO - MYGN | 34% Loosely correlated | +1.22% | ||
| ATEC - MYGN | 34% Loosely correlated | -2.20% | ||
More | ||||